Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Certainly an interesting IMC.
If you were to believe Greg's words then this is the mother of all opportunities but the facts don't back it up. He also went on to answer my question by saying that they can't speak for the analysts guidance yet previously they were RNS'ing Hardman Research broker notes to the market and encouraging us all to read. I find his comments on how happy they are with the current growth trajectory to be downright disingenuous.
Greg continually claimed Shield can reach cash flow break even in H2 2025 without further funding, I call BS. I will watch with interest and will happily eat my hat, feathers and all, if proved wrong.
Once the market wakes up....catch a grip man.
Greg since arrival has presided over failure after failure. The goal posts keep getting moved and just expect another fund raise its probably priced in.
330k scripts in 2024,.....28.8k isn't actually a great start. If they get anywhere close to half that by year end it will be wonderful. However I doubt even that.
If good news is a 1% rise Q on Q I'd hate to see what bad news is.
GLA, ADYOR
Its online - webinar.
Nope, I do not attend shareholders meetings, too much travel and long days from Lincs.
Quote "Additionally, our stated initiatives to improve the average net selling price by increasing PA submission rates and more favorable Medicaid pricing following renegotiation of payer contracts, are progressing very well."
At this stage, they have successfully extended their financing and got improved terms on its existing $20 million debt financing with SWK Funding.
Let us know how it goes, still hoping for a blue day :)
Optrade, will you be attending today's investor meet ?
I will be for sure, want to see what their plans are to generate more revenue
Your Quote "The only thing going for you is that the value is low enough already that it might not crash further"
Yes, it's very undervalued, a good reason to BUY!
For your info, the results have been consistently strong and I don't see that there is anything in what you say will that stop it despite your built-up hate and dislike of the CEO.
Optrade last post from me as I don't want to upset you.
...But that couldn't be further from the truth. They did have sales momentum but it's totally lost. QoQ growth rate has dropped from 60% to 1% - that wouldn't be so bad if they were maturing at over 100k prescriptions per quarter but they are still only where they were meant to be last year before the full sales team had settled in.
The second key metric, net selling price, has also gone backwards this quarter too.
The only thing going for you is that the value is low enough already that it might not crash further, but there are now serious question marks around this management team and tbh, possibly even the product which is failing to gain traction.
GL, I hope this works out for you!
SMY, Shield is a small company with an experienced accountant who should control costs, their sales staff will be on high commissions. For what it's worth I don't care too much if they don't achieve the growth as fast as they want. They have a good product with a sales momentum that will be hard to stop so I believe they will continue to grow and be a profitable successful company.
I'm here for the long-term so it would be great it all the short-term negative posters move on without making things worse than what they are.
Optrade,
do you actually believe all the figures and the targets will be reached.?
They have been circa 50% of any target set previously so will it suddenly all change?
Good luck in your belief this will rocket today....lol
if it closes blue it will be fantastic
Why are you still here if you don't see anything positive in the results?
They are good enough to secure a large loan with no dilution of shares, once the market wakes up the SP is likely to bounce from these burnt-out low levels.
Are you joking?
Business Update and Audited Results April 2023 - Funded to support operations through to cash flow break-even by end of 2024
28th September 2023 - cash raise and new $20m debt facility
They are funded to cash flow break even if they totally reverse the course they are on, but that's completely unrealistic now. How they will go from 1% QoQ growth to nigh on 50% needs to be clearly explained by Greg later or it's simply bollo***
I dare to dream that your statement might come true. However I'm long enough here to realise that they burn through cash, do not have a great sales record across Europe, delays in China, Korea.
No mention in results about other parts of the world.
No dilution + Cash runway to breakeven + sales metrics improving
Most important bits
80%? I think you are being a bit too pessimistic actually.
But we seem to agree that today is likely to be a not insignificant red day :)
This is the time to BUY
ATL
Cashed up
Business moving forward
Recovery stock from here
27750 was the number of prescriptions they reported in Q3 of last year, before then downgrading it in q4.
So Shield are now at the level we all thought they were six months ago. Really poor. Was looking to buy in if there were any green shoots but it's tough to see where they go from here?
Topped up 100,000 1.34P very happy, anyone buying today at under 2P should do well
Against Hardmans research of 65k, 28.8 is more than 50% of target. And a hell off a way of 45k, as a said before we need a complete step change in the company & we didn't get it.
Shocking....
£1.2 million for Europe, its time to cut ties & get a new partner. Look at the size of Germany, France, Spain, etc and all we can get us 1.2 million.
A shambles in Texas wiping out gains elsewhere.
A big boast about a 310% increase when in actual fact you missed your own revised down target by 40%.
Certainly not the greatest set of results but better than expected, and nothing to write home and tell your granny about & really nothing to be proud of.
Should do 80% today on that news
Sure, if you are short, maybe! Lol.
Fantastic result.
Q3 2023 - $8,500,000
Q4 2023 - $14,500,000
Q1 2024- $15,000,000
Q2 2024 -$16,500,000
Q3 2024 - $22,500,000
Q4 2024 - $31,500,000
Q1 2025 - $38,900,000
Looks ok to me :)
Q2 2025+
$45,700,000
HarChris: Like you, I see nothing in this update to justify the optimism shown by a couple of the other posters.
It is, however, consistent with how this operation rolls though.
Still very much on track to end up how I suggested this one is likely to.
Did I miss the part about what action they have taken against that third party, who they previously blamed for those false prescription numbers? Or has it all been forgiven and forgotten? Lol.
A zombie outfit, to all intents and purposes in my sincere opinion - but this is AIM, so who knows, the SP might have a spike.